{"filings":[{"id":991877,"accession_number":"0001213900-26-067711","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-06-11T16:43:58+00:00","items":["1.01","5.03","5.02","2.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Adial completes reverse merger with Azora, issues ~87% of shares to Azora holders, raises $26.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Former Azora equityholders will hold ~51.0% of pro forma fully diluted common stock; pre-merger Adial holders ~7.7%.","Initial PIPE closing expected June 12, 2026; gross proceeds $26.8M from sale of Pre-Funded Warrants at $2.7489 each.","Company guaranteed and then exchanged $5.5M Azora convertible notes for Pre-Funded Warrants covering 2,031,603 shares.","Stockholders must approve conversion of Series A Preferred, exercise of options/warrants, and a reverse stock split.","Wendy Young appointed to the Board; 180-day lock-up agreements signed with certain shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":34,"accession_number":"0001213900-26-054219","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-05-11T12:40:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adial Pharma Q1 net loss $2M; cash $4.6M; FDA policy shift may aid AD04 path","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $4.6M as of Mar 31, 2026, down from $5.9M at Dec 31, 2025; runway into H2 2026.","Net loss $2.0M vs $2.2M YoY; R&D expenses down 42% to $433K; G&A up 3% to $1.6M.","FDA signals possible single pivotal trial for AD04; bipartisan AUD legislation introduced.","Established collaboration framework with Molteni Farmaceutici for European commercial pathway.","International patent application published; if granted, AD04 protection extended to 2045."],"consensus_eps_estimate":-2.7846,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93310,"accession_number":"0001213900-26-042057","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adial grants RSAs to CEO, CFO, COO, and directors; options to director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Cary Claiborne receives 37,985 RSAs (28,800 as CEO, 9,185 as director).","CFO Vinay Shah receives 17,325 RSAs; COO Tony Goodman receives 26,510 RSAs.","Directors Schuyler and Gilliland each get 9,185 RSAs; Anderson gets options for 9,185 shares at $1.64.","All awards vest on the earlier of one-year anniversary or change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104831,"accession_number":"0001213900-26-024336","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adial Pharmaceuticals FY2025 net loss $8M, cash $5.9M; advancing AD04 toward Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.0M in FY2025 vs $13.2M in FY2024, driven by lower R&D and 2024 one-time $4.5M inducement expense.","Cash and cash equivalents $5.9M as of Dec 31, 2025, up from $3.8M; expected to fund operations into H2 2026.","Entered collaboration framework with Molteni for European AD04 commercialization; potential value ~$60M if successful.","Regained Nasdaq minimum bid price compliance on Feb 23, 2026; matter now closed.","Completed EOP2 meeting with FDA; secured U.S. manufacturing partners Cambrex and Thermo Fisher for late-stage development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104830,"accession_number":"0001213900-26-022718","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adial signs exclusive AD04 collaboration framework with Molteni for Europe; potential $60M in milestones and royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration framework with Molteni Farmaceutici for exclusive AD04 commercialization in Europe; definitive agreement pending.","Total potential aggregate value from royalties (high single to low double digits) and milestones estimated at nearly $60M.","Molteni granted exclusivity for due diligence; upfront and milestone payments expected upon final agreement.","AD04 is a genotype-driven Alcohol Use Disorder therapy; company also advancing US partner discussions.","Special meeting on Feb 26 lacked quorum; company must call new meeting every 90 days until warrant approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104829,"accession_number":"0001213900-26-019639","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals regains Nasdaq minimum bid price compliance; highlights advanced AD04 partnering discussions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb. 23, 2026 that closing bid price was ≥$1.00 for 10 consecutive business days (Feb. 6-20, 2026).","Nasdaq confirmed compliance with Listing Rule 5550(a)(2) and closed the matter.","CEO Cary Claiborne stated the company is engaged in advanced strategic partnering discussions for AD04.","AD04 is a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder, moving toward Phase 3 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104828,"accession_number":"0001213900-26-012274","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals announces 1-for-25 reverse stock split to meet Nasdaq $1 minimum bid price","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split reduces shares from ~27.8M to ~1.1M; effective 11:59 p.m. ET on Feb 5, 2026.","Split-adjusted trading begins Feb 6 under symbol ADIL; new CUSIP 00688A304; cash for fractional shares.","Goal: regain compliance with Nasdaq minimum $1 bid price; no assurance of desired effect.","Proportional adjustments to equity awards and warrants; authorized shares unchanged.","CEO Claiborne cites progress on AD04 for Alcohol Use Disorder and partnering strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104827,"accession_number":"0001213900-26-001790","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adial Pharmaceuticals director James W. Newman Jr. resigns from Board effective Jan 5, 2026","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["James W. Newman Jr. resigned as director and member of Audit and Compensation Committees, effective January 5, 2026.","No disagreement with company operations, policies or practices cited.","No replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121103,"accession_number":"0001213900-25-116666","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals raises $2.86M via warrant inducement; issues new Series F warrants for up to 13.8M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercised 9,215,675 existing Series C-1 and E warrants at $0.31/share, generating gross proceeds of $2.86M.","In consideration, company issued new unregistered Series F warrants to purchase up to 13,823,512 shares at $0.31.","New warrants exercisable only after stockholder approval, term 24 months from approval date; company must seek approval within 120 days of closing.","Company agreed to 60-day standstill on equity issuances (except ATM after 31 days) and 6-month no variable rate transactions.","A.G.P./Alliance Global Partners acted as financial advisor with an 8% fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121102,"accession_number":"0001213900-25-110385","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adial reports Q3 net loss $1.8M, cash $4.6M; FDA provides Phase 3 guidance for AD04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.8M for Q3 2025 vs $2.2M in Q3 2024; R&D expenses down 50% YoY.","Cash and equivalents $4.6M at Sep 30, 2025; runway into Q2 2026.","Successful End of Phase 2 meeting with FDA; obtained guidance on Phase 3 design for AD04 (AUD).","Analytical validation of cheek swab test with Genomind for biomarker-positive patients; FDA confirmed NSR, no IDE needed.","Patent protection extended to at least 2045 via provisional patent update filed July 2025."],"consensus_eps_estimate":-3.57,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137734,"accession_number":"0001213900-25-087925","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals receives FDA alignment on Phase 3 trial design for AD04 in alcohol use disorder","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA End-of-Phase 2 meeting held July 29, 2025; final minutes received confirming alignment on adaptive Phase 3 design.","FDA confirmed primary endpoint of zero heavy drinking days during months 5 and 6 of efficacy observation.","FDA supported biomarker stratification (AG+ subgroup, ~14% of general population) and adaptive enrichment strategy.","FDA advised pre-specifying key secondary endpoints in protocol for potential future product labeling.","CEO highlights new patent filing that may extend AD04 market exclusivity to 2045."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137733,"accession_number":"0001213900-25-083719","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals granted 180-day Nasdaq extension to meet $1.00 bid price rule by March 2, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq extension until March 2, 2026 to regain compliance with minimum $1.00 bid price requirement.","Initial 180-day compliance period ended September 1, 2025; extension granted due to meeting other listing criteria.","Company must maintain closing bid ≥ $1.00 for 10 consecutive business days before deadline.","If necessary, company will consider a reverse stock split to cure deficiency.","No immediate effect on trading; stock continues on Nasdaq Capital Market under symbol ADIL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137732,"accession_number":"0001213900-25-076085","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adial reports FDA agreement on Phase 3 design for AD04; Q2 net loss $2.0M, cash $5.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed End of Phase 2 meeting with FDA; agreement on key Phase 3 protocol elements for AD04 in Alcohol Use Disorder.","Cash and equivalents $5.9M as of June 30, 2025 (up from $2.4M at March 31); cash runway into Q2 2026.","Public offering closed June 17, 2025 raised net proceeds ~$3.0M from 11.1M shares and warrants at $0.3251.","Entered manufacturing agreements with Thermo Fisher Scientific and Cambrex for AD04 drug product and substance.","Regained Nasdaq compliance on July 14, 2025 for minimum stockholders' equity of $2.5M."],"consensus_eps_estimate":-6.375,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137731,"accession_number":"0001213900-25-070671","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Adial enters new ATM facility for up to $4.98M; terminates prior HCW Wainwright ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM sales agreement with A.G.P./Alliance Global Partners for up to $4,983,000 of common stock.","Sales agent commission of 3.0% of gross proceeds; expense reimbursement up to $50k initial plus quarterly fees.","Prior ATM with H.C. Wainwright terminated July 31, 2025; had raised ~$4M net from 2.35M shares.","Company not obligated to sell shares; sales may be suspended at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137730,"accession_number":"0001213900-25-070642","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Adial shareholders approve authorized share increase, reverse split, and equity plan amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved increase in authorized common stock from 50M to 100M shares, effective August 1, 2025.","Approved reverse stock split at a ratio of 1-for-2 to 1-for-25, with ratio set by Board.","Approved Amendment No. 7 to 2017 Equity Plan, increasing reserved shares from 2M to 5M.","Approved issuance of up to 6.73M shares upon exercise of Series B-1/C-1 warrants from May 2025 offering.","Approved issuance of up to 19.425M shares upon exercise of Series D/E warrants from June 2025 offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137729,"accession_number":"0001213900-25-064467","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Adial Pharmaceuticals regains Nasdaq compliance with stockholders' equity requirement after $3.6M offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with Listing Rule 5550(b)(1) as of July 14, 2025.","Deficiency arose from $2.13M equity as of Mar 31, 2025, below $2.5M minimum.","June 2025 best-efforts offering raised ~$3.6M gross via shares and warrants.","Nasdaq will monitor ongoing compliance; next periodic report may trigger re-evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137728,"accession_number":"0001213900-25-062800","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Adial Pharmaceuticals regains Nasdaq equity compliance after $3.6M offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on May 23, 2025 for stockholders' equity of $2,126,662, below $2.5M minimum.","Completed June 18, 2025 offering raising ~$3.6M gross via shares and warrants at $0.3251 per unit.","Company believes it has now regained compliance with Nasdaq stockholders' equity requirement.","Nasdaq will continue to monitor compliance; further non-compliance could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155123,"accession_number":"0001213900-25-055700","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals closes $3.6M public offering of common stock and warrants; amends existing warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.6M from sale of 11.1M shares (or equivalents) plus Series D and E warrants at $0.3251/unit.","Series D warrants exercisable at $0.35, expire 5 years after stockholder approval; Series E warrants expire 18 months post-approval.","Existing Series B-1 and C-1 warrants amended: exercise price cut from $0.74 to $0.35, expiration extended to 2030 and 2026 respectively.","Offering closed June 18, 2025; net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155122,"accession_number":"0001213900-25-054839","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Adial Pharmaceuticals postpones 2025 Annual Meeting to August 1, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting date moved from prior schedule to August 1, 2025; record date remains June 4, 2025.","Stockholders planning to solicit proxies for non-management director nominees must provide Rule 14a-19 notice by June 26, 2025.","Meeting time and location to be detailed in amended definitive proxy statement to be filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155121,"accession_number":"0001213900-25-049451","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Adial Pharmaceuticals receives Nasdaq delisting notice for equity below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $2,126,662 as of March 31, 2025, below Nasdaq's $2.5M requirement.","Company has 45 calendar days (until July 7, 2025) to submit a compliance plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180 days extension to regain compliance.","Failure to regain compliance could lead to delisting; company may request a hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155120,"accession_number":"0001213900-25-043733","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.08","8.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals sets 2025 Annual Meeting for July 24; proposal deadlines revised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for July 24, 2025; record date June 4, 2025.","Rule 14a-8 stockholder proposal deadline: May 25, 2025.","Director nominations and non-14a-8 proposals due by May 25, 2025.","Universal proxy rule compliance notice also due May 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155119,"accession_number":"0001213900-25-043730","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adial Pharma Q1 net loss $2.2M; warrants raise $2.75M; AD04 Phase 2 meeting set for July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $2.4M at March 31; with $2.75M warrant proceeds, runway into Q4 2025.","Net loss $2.2M vs $6.5M YoY; reduction due to $4.5M 2024 inducement expense not recurring.","Entered warrant inducement: exercised 3.7M shares at $0.74, gross proceeds ~$2.75M.","Received six-figure milestone from Adovate for asthma candidate Phase 1; eligible for up to $83M in milestones plus royalties.","FDA supports 505(b)(2) bridging strategy; End of Phase 2 meeting planned for July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155118,"accession_number":"0001213900-25-040724","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Adial raises $2.75M via warrant inducement; existing warrants exercised at $0.74","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing Series B and C warrants for 3,718,440 shares exercised at reduced price of $0.74 per share.","Company issued new unregistered Series B-1 (2.48M shares) and C-1 (4.03M shares) warrants at $0.74 exercise price.","New warrants exercisable only after stockholder approval; Series B-1 expire in 5 years, C-1 in 18 months.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155117,"accession_number":"0001213900-25-038442","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals replaces auditor Marcum with CBIZ CPAs effective April 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor; CBIZ CPAs engaged for FY 2025, effective immediately.","Marcum's reports for FY 2024 and 2023 included a going-concern explanatory paragraph but no adverse opinion.","No disagreements with Marcum; previously reported material weaknesses in internal controls continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173645,"accession_number":"0001013762-25-000999","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adial Pharmaceuticals appoints Tony Goodman as COO with $300K base salary, three-year term","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony Goodman appointed Chief Operating Officer effective April 1, 2025, under three-year employment agreement.","Base salary of $300,000 per year; eligible for discretionary bonus up to 30% of base.","Severance: six months for without-cause termination; 12 months if termination follows a change of control.","Goodman had been serving as COO since January 2024 via consulting agreement with The Keswick Group; that agreement terminates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173644,"accession_number":"0001213900-25-021738","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Adial Pharma receives Nasdaq bid price deficiency notice; compliance deadline Sept 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice March 5, 2025 for failing minimum bid price of $1.00 for 30 consecutive business days (Jan 17 - Mar 4, 2025).","No immediate effect on listing or trading; common stock continues on Nasdaq Capital Market under symbol ADIL.","Company has until September 1, 2025 (180 days) to regain compliance by achieving $1.00 closing bid for 10 consecutive days.","If noncompliant by Sept 1, Company may be eligible for additional 180-day period if meets other listing standards.","Company considering available options, including a reverse stock split, to cure the bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173643,"accession_number":"0001213900-25-019779","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adial Pharma FY2024 net loss $13.2M, cash $3.8M; FDA confirms AD04 505(b)(2) path","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.2M in FY2024 versus $5.1M in FY2023; widened primarily on $4.5M non-cash inducement charge.","Cash and equivalents $3.8M at year-end; expects to fund operations into H2 2025.","R&D spend rose $1.9M (+155%) driven by PK study and CMC manufacturing for AD04 Phase 3.","FDA confirmed 505(b)(2) bridging strategy; Phase 3 trial to begin in 2025.","Appointed Vinay Shah as CFO in November 2024; secured three new U.S. patents for AD04 genetic diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173642,"accession_number":"0001213900-25-016826","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adial gets FDA nod for AD04 in vitro bridging strategy; Phase 3 path clear","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed with proposed 505(b)(2) bridging strategy for AD04, leveraging AD04-103 study and in vitro data.","Adial to manufacture clinical supplies for Phase 3 program in 2025 following FDA confirmation.","Submission was made on Nov 19, 2024; FDA feedback received Feb 25, 2025.","AD04 is a genetically targeted therapy for Alcohol Use Disorder; ONWARD Phase 3 trial completed.","CEO Cary Claiborne says milestone brings AD04 closer to regulatory approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173641,"accession_number":"0001213900-25-002855","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals updates business development presentation for upcoming meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company will hold business development meetings over the next several weeks.","Updated business development presentation furnished as Exhibit 99.1.","Presentation includes forward-looking statements under safe harbor provisions.","No specific financial data, milestones, or material changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173640,"accession_number":"0001213900-25-002106","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"No material new facts identifiable in January 2025 corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation content not reproduced in the 8-K; only forward-looking language and boilerplate visible.","No specific pipeline, financial, or clinical milestones disclosed in the filing excerpt.","Event is a routine corporate presentation update; provides no directional signal for investors.","Ticker ADIL referenced; no other counterparties or material events mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190609,"accession_number":"0001213900-24-110191","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01","1.02","3.02","9.01"],"status":"ready","headline":"Adial enters $5M equity purchase agreement with Alumni Capital, terminates prior deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company can sell up to $5M (option to $10M) of common stock to Alumni Capital at 97% of VWAP, with $0.55/share floor.","Issued 68,807 commitment shares as consideration; prior May 2023 agreement terminated.","Sales at Company's discretion; proceeds for strategic opportunities, working capital, general corporate purposes.","Agreement runs through Dec 31, 2026; Company can terminate on 10 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190608,"accession_number":"0001213900-24-106554","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Cary Claiborne signs new 3-year deal at Adial; bonus target raised to 50%, 350K option grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New three-year employment agreement effective Dec 5, 2024, replaces prior agreement from Dec 2021.","Base salary remains $489,250; annual bonus target increased to 50% of base salary.","Granted 350,000 stock options vesting pro rata monthly over 36 months.","Agreement provides for severance and change-in-control protections per detailed terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190607,"accession_number":"0001213900-24-099633","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals Announces Positive Topline Results from AD04 Pharmacokinetics Study for Alcohol Use Disorder","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Study enrolled 30 healthy volunteers in two cohorts: Cohort 1 (n=6) evaluated PK variability; Cohort 2 (n=24) assessed relative bioavailability, dose proportionality, and food effect.","Results showed AD04 0.33mg delivered lower ondansetron PK exposure than marketed 4mg tablet; exposure increased proportionally across 3-fold dose range; no food effect observed.","Completion of the study satisfied an FDA requirement for the upcoming Phase 3 clinical trials of AD04 and supports 505(b)(2) regulatory pathway.","Company plans to engage with FDA in Q4 2024 to discuss study design for Phase 3, aiming to enhance likelihood of success and advance partnership discussions.","Continued excellent safety and tolerability findings consistent with extensive human use experience with ondansetron."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190606,"accession_number":"0001213900-24-096796","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Adial stockholders approve 4x increase in equity plan shares to 2M; directors re-elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 6 to 2017 Equity Incentive Plan approved, raising authorized shares from 500,000 to 2,000,000.","J. Kermit Anderson and James W. Newman Jr. re-elected as Class III directors through 2027.","Marcum LLP ratified as independent auditor for fiscal year ending December 31, 2024.","Advisory vote on executive compensation approved; board sets future advisory vote every three years.","Broker non-votes of ~2.3M shares on director election and plan amendment, reflecting significant institutional abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190605,"accession_number":"0001213900-24-094344","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adial Pharmaceuticals appoints Vinay Shah as CFO effective Nov 16, 2024; Joseph Truluck resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Joseph Truluck resigns effective Nov 15, 2024; will serve as consultant through Mar 31, 2025.","Vinay Shah appointed CFO effective Nov 16, 2024, with a 3-year employment term.","Shah receives $315K annual base salary, up to 30% discretionary bonus, and 40,000 stock options.","Shah previously served as CFO at Virpax (VRPX) and Aravive (ARAV), with over 25 years industry experience.","Truluck's resignation was not due to any disagreement with the company over operations or accounting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224437,"accession_number":"0001213900-24-036613","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adial Pharmaceuticals enters separation agreement with Dr. Bankole Johnson; consulting termination May 17, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation agreement with Dr. Bankole Johnson signed April 22, 2024; consulting termination effective May 17, 2024.","One-time separation fee of $54,375; may continue consulting at $850/hour with prior approval.","Up to $225,000 in milestone payments if certain goals achieved by December 31, 2024.","Agreement includes general release of claims, confidentiality, and mutual nondisparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224436,"accession_number":"0001213900-24-034186","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals enters ATM equity offering of up to $4.28M with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At-the-market offering of common stock up to $4,283,650 based on Form S-3 limitations.","Sales agent H.C. Wainwright receives 3% commission on gross proceeds from each sale.","Company to reimburse Wainwright up to $50,000 in expenses, plus $2,500 per due diligence update.","Offering continues until all shares sold or the agreement is terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224435,"accession_number":"0001213900-24-033471","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adial Pharmaceuticals terminates CMO Dr. Bankole A. Johnson, effective May 17, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Company provided notice to Dr. Johnson on April 10, 2024, terminating consulting agreement.","Termination effective May 17, 2024; Dr. Johnson will no longer serve as Chief Medical Officer.","No successor or replacement Chief Medical Officer announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243744,"accession_number":"0001213900-24-020440","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Adial raises $3.5M via warrant exercise, issues new 2.3M-share warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.5M from cash exercise of 1.15M existing warrants at $2.82/share; H.C. Wainwright placement agent.","Incentive: new unregistered Series C warrants to buy up to 2.3M shares at $2.82, exercisable for 18 months.","Holder paid $0.125 per new warrant; placement agent fees: 7% cash + 1% management + $25k expense + $50k legal.","Proceeds to fund working capital and clinical activities for lead drug AD04 targeting Alcohol Use Disorder.","Company to file resale registration statement for new warrant shares within 45 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243743,"accession_number":"0001213900-24-004505","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals appoints Tony Goodman as COO effective Jan 17, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony Goodman appointed COO effective Jan 17, 2024; continues as board director.","Compensation $25k/month, must devote ≥75% business time to role.","Will lead strategic growth, clinical development & commercial planning for AD04 (AUD treatment).","Former Chief Business Development Officer at Indivior; helped grow addiction market revenue >$1B.","Appointment via Statement of Work #2 under existing Master Services Agreement with The Keswick Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243742,"accession_number":"0001213900-24-003750","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Adial shareholders approve issuance of up to 3.0M shares upon warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 approved: 432,915 for, 51,550 against, 6,621 abstain; enables exercise of warrants from Oct 2023 private placement.","Proposal 2 (adjournment) also approved but not needed; votes: 436,338 for, 47,809 against, 6,939 abstain.","Warrant exercise could dilute existing common stock by over 20%, subject to Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261148,"accession_number":"0001213900-23-091094","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals regains compliance with Nasdaq stockholders' equity minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5M stockholders' equity.","Nasdaq will monitor compliance; failure to show compliance in next periodic report could lead to delisting.","Company issued press release on November 29, 2023 announcing the compliance notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261147,"accession_number":"0001213900-23-090561","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals receives Nasdaq deficiency notice but believes private placement restores compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 21, 2023 for stockholders' equity of $2.34M below $2.5M minimum.","Private placement closed Oct 2023 raised ~$3.5M net, boosting equity above threshold.","Company believes it now satisfies the Rule and may not need to submit a compliance plan.","Nasdaq will monitor compliance at next periodic report; delisting remains possible if equity drops again."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261146,"accession_number":"0001213900-23-087129","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adial Pharma Q3 net loss narrows to $1.4M; $4M private placement extends runway into Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.4M in Q3 2023, down 55% from $3.1M in Q3 2022.","R&D expenses decreased $489K (70%) YoY as AD04 trial activities wound down.","G&A expenses decreased $708K (38%) YoY due to lower compensation and headcount.","Cash $315K at Sep 30; $4M private placement (net $3.5M) completed post-quarter extends runway into Q4 2024.","Planning two parallel Phase 3 trials for AD04; in confidentiality agreements with potential partners."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261145,"accession_number":"0001213900-23-083634","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Adial shareholders approve equity plan amendment increasing authorized shares to 500,000; re-elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Amendment No. 5 to 2017 Equity Incentive Plan, increasing shares from 380,000 to 500,000.","Cary J. Claiborne and Robertson H. Gilliland re-elected as Class II directors for three-year terms.","Marcum LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261143,"accession_number":"0001213900-23-081590","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K/A","filed_at":"2023-10-30T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals amends 8-K to correct Purnovate sale closing date to August 17, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected earliest event date from June 30 to August 17, 2023 for sale of Purnovate assets to Adovate.","Sale consideration included $450k upfront, 19.99% equity in Adovate, expense reimbursement, and milestone payments up to ~$11M (development/approval) and $50M (commercial).","No other changes to original 8-K; prior financial disclosures and terms remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261144,"accession_number":"0001013762-23-006323","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Adial raises $4M in private placement; issues warrants at $2.82","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4M from sale of 1.42M shares (or pre-funded warrants) and series A/B warrants.","Net proceeds ~$3.5M after fees; to fund AD04 clinical activities and working capital.","Warrants exercisable at $2.82/share after stockholder approval; Series A 5.5yr, Series B 18mo.","Company must file resale registration within 20 days, effective within 75 days.","60-day lock-up on new issuances; 1-year ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278417,"accession_number":"0001213900-23-079677","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adial recasts 2022 and 2021 financials to reflect Purnovate discontinued ops after sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed sale of Purnovate assets and business to Adovate, LLC on June 30, 2023.","Historical Purnovate results now shown as discontinued operations for 2022 and 2021.","Only Item 7 (MD&A) and Item 8 (Financial Statements) are revised; other 10-K sections unchanged.","Company directs investors to Q1 and Q2 2023 Form 10-Qs for more recent developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278416,"accession_number":"0001213900-23-078339","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Adial finalizes Purnovate asset sale to Adovate; director Stilley resigns","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Final acquisition agreement with Adovate for Purnovate assets effective June 30, 2023.","Reimbursable expenses of $1.05M: $350K paid June 30, $350K paid Sept 20, $350K due by Dec 2, 2023.","Adial receives 3.46M Class A units (15% equity) in Adovate with anti-dilution until $4M cumulative funding.","Potential milestone payments per compound (development, approval, commercial) and royalties on net sales; amounts redacted.","Board member William B. Stilley resigned effective Sept 18, 2023, not related to any disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278415,"accession_number":"0001213900-23-075549","cik":1513525,"company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adial Pharmaceuticals to present at H.C. Wainwright conference; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company will present at H.C. Wainwright 25th Annual Global Investment Conference Sept 11-13, 2023.","Investor presentation furnished as Exhibit 99.1 contains no new financial or operational data.","No earnings, guidance, or pipeline milestones announced in this filing.","Filing is procedural under Regulation FD; presentation includes standard forward-looking statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5419932.193305439,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-09-11T23:59:59+00:00|278415"}